Market Cap : 31.87 B | Enterprise Value : 35.02 B | PE Ratio : 15.66 | PB Ratio : 2.68 |
---|
NAS:BIIB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:BIIB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Biogen has the Profitability Rank of 9. It has a higher profitability and may stay that way.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Biogen's Operating Margin % for the quarter that ended in Jun. 2022 was 35.03%. As of today, Biogen's Piotroski F-Score is 6.
For the Drug Manufacturers - General subindustry, Biogen's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Biogen's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Biogen's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Biogen has the Profitability Rank of 9. It has a higher profitability and may stay that way.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Biogen's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as:
Operating Margin % | = | Operating Income (Q: Jun. 2022 ) | / | Revenue (Q: Jun. 2022 ) |
= | 907 | / | 2589.1 | |
= | 35.03 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Biogen has an F-score of 6 indicating the company's financial situation is typical for a stable company.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Warning Sign:
Biogen Inc operating margin has been in a 5-year decline. The average rate of decline per year is -11.1%.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Biogen's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Murphy Nicole | officer: Head of Pharm Ops and Tech | BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 |
Izzar Rachid | officer: Head of Alzheimer's Disease | BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 |
Jones William D /ca/ | director | |
Freire Maria C | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC 26 NORTH EUCLID AVENUE PASADENA CA 91101 |
Mcdonnell Michael R | officer: EVP, Chief Financial Officer | C/O IQVIA HOLDINGS INC. 83 WOOSTER HEIGHTS ROAD DANBURY CT 06810 |
Galdes Alphonse | officer: EVP Pharmaceutical Oper & Tech | BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
Hawkins William A | director | MEDTRONIC INC 710 MEDTRONIC PKWY, MS LC310 MINNEAPOLIS MN 55432-5604 |
Mantas Jesus B | director | BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 |
Kramer Robin | officer: VP, Chief Accounting Officer | 999 VANDERBILT BEACH ROAD 3RD FLOOR NAPLES FL 34109 |
Karp Daniel | officer: EVP, Corporate Development | 225 BINNEY STREET CAMBRIDGE MA 02142 |
Capello Jeffrey D | officer: EVP & Chief Financial Officer | BOSTON SCIENTIFIC CORPORATION ONE BOSTON SCIENTIFIC PLACE NATICK MA 01760 |
Guindo Chirfi | officer: EVP Glob. Mkt Acc & Cust Innov | C/O BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
Gregory Ginger | officer: EVP, Human Resources | C/O BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
Kress Jean-paul | officer: EVP Pres Int'l & Global Hd GTO | 215 FIRST STREET, SUITE 415 CAMBRIDGE MA 02142 |
Mckenzie Paul | officer: EVP Pharmaceutical Oper & Tech | BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142 |
From GuruFocus
Other Sources
By Seekingalpha 2022-03-07
By Zacks 2022-03-30
By Zacks 2022-03-10
By Zacks 2022-02-10
By Zacks 2022-03-01
By tipranks.com 2022-03-07
By Fool 2022-02-19
By Zacks 2022-04-04
By Zacks 2022-03-10
By Zacks 2022-02-25
By Zacks 2022-04-04
By Zacks 2022-03-04
By Zacks 2022-03-29